20/20 Biolabs, Inc. Common Stock (AIDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, 20/20 Biolabs, Inc. Common Stock (AIDX) has a cash flow conversion efficiency ratio of -0.350x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-536.45K) by net assets ($1.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of 20/20 Biolabs, Inc. Common Stock for the company's overall valuation and market capitalisation.
20/20 Biolabs, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how 20/20 Biolabs, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
20/20 Biolabs, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 20/20 Biolabs, Inc. Common Stock ranked by their cash flow conversion efficiency. Explore how high is 20/20 Biolabs, Inc. Common Stock's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vinny Overseas Limited
NSE:VINNY
|
0.031x |
|
Samchai Steel Industries Public Company Limited
BK:SAM
|
-0.061x |
|
JATCORP LTD.
F:3J2
|
N/A |
|
Rectifier Technologies Ltd
AU:RFT
|
-0.072x |
|
Proactis SA
PA:PROAC
|
5.290x |
|
Tatton Asset Management plc
LSE:TAM
|
0.317x |
|
Kontigo Care AB
ST:KONT
|
0.046x |
|
Astrotech Corp
NASDAQ:ASTC
|
-0.228x |
Annual Cash Flow Conversion Efficiency for 20/20 Biolabs, Inc. Common Stock (2016–2024)
The table below shows the annual cash flow conversion efficiency of 20/20 Biolabs, Inc. Common Stock from 2016 to 2024. View AIDX stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.53 Million | $-2.60 Million | -1.694x | -56.91% |
| 2023-12-31 | $4.29 Million | $-4.63 Million | -1.080x | -274.38% |
| 2022-12-31 | $9.37 Million | $5.80 Million | 0.619x | +497.12% |
| 2021-12-31 | $6.89 Million | $-1.07 Million | -0.156x | +74.07% |
| 2020-12-31 | $3.39 Million | $-2.04 Million | -0.601x | +39.14% |
| 2019-12-31 | $2.15 Million | $-2.12 Million | -0.988x | -146.80% |
| 2018-12-31 | $3.28 Million | $-1.31 Million | -0.400x | +82.79% |
| 2017-12-31 | $456.18K | $-1.06 Million | -2.325x | +3.73% |
| 2016-12-31 | $784.36K | $-1.89 Million | -2.415x | -- |
About 20/20 Biolabs, Inc. Common Stock
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (… Read more